Updated just now · Live
Stock analysis, price data, and AI-powered insights for TG Therapeutics Inc (TGTX).
TG Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for TGTX.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). TGTX Stock Intelligence Report. [stoxpulse.com/stocks/tgtx]
Disclaimer: The information on this page about TG Therapeutics Inc (TGTX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for TG Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Gro...
1d ago
TG Therapeutics: Flawless Execution And $500 Milli...
2d ago
StoxPulse AI results for TGTX: Pulse Score 59/100. Primary sentiment trends from 4 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$5.90B
P/E Ratio
—
EPS
$2.43
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
TG Therapeutics Completes Enrollment In A Phase 3 Trial Evaluating Subcutaneous BRIUMVI, Its Anti-CD20 Monoclonal Antibody, In People With Relapsing Forms Of Multiple Sclerosis
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI